Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status

BACKGROUND: Leptomeningeal metastasis (LM) is a catastrophic complication for patients with non-small cell lung cancer (NSCLC) and carries an extremely poor prognosis. The efficacy of osimertinib 80 mg once daily for epidermal growth factor receptor-mutated (EGFRm) NSCLC with LM has yet to be fully...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Haiyan, Chen, Hengqi, Kong, Jianxin, Zhang, Ye, Liu, Shan, Yang, Guangjian, Yang, Lu, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263890/
https://www.ncbi.nlm.nih.gov/pubmed/34350252
http://dx.doi.org/10.21037/atm-21-1249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263890/
https://www.ncbi.nlm.nih.gov/pubmed/34350252
http://dx.doi.org/10.21037/atm-21-1249

Ejemplares similares